Protocol Ledger

Therapeutic Cohort END · ClinicalTrials.gov API v2

Endocrinology, Obesity, and Metabolic: Phase II & III Clinical Trial Benchmarks

Protocol Ledger tracks 2,382 interventional Phase II and Phase III Endocrinology, Obesity, and Metabolic protocols registered from 2018 through 2026, including 857 active studies, 1,032 completed studies, and 219 early-stopped studies (9.19% overall; 17.51% of closed trials).

Median Enrollment: 113.0 participants Median Completed Span: 616 days California Share: 658 studies (27.6%)

1. Reconciled Endocrinology, Obesity, and Metabolic Execution & Stop-Cause Profile

Endocrinology, Obesity, and Metabolic Cohort Metrics (Publication 47c4426df7e9d67d5bfe)
Clinical Trial Metric Verified Value Operational Context
Total Phase II & III Protocols (2018 to 2026) 2,382 Deterministic primary MeSH and condition-keyword assignment
Active Concurrent Pipeline 857 Recruiting, enrolling by invitation, and active follow-up protocols
Completed vs Prematurely Stopped 1,032 / 219 17.51% closed-trial attrition ratio across 1,251 closed protocols
Slow Accrual vs Safety & Futility Stops 40 / 25 / 10 Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5)
Physical Hospital Site Disclosure Rate 86.3% Named hospital campus participations vs anonymized CRO site slots

2. Leading Consolidated Trial Sponsors Focused on Endocrinology, Obesity, and Metabolic

Consolidated Biopharma, Academic & Federal Sponsors (Endocrinology, Obesity, and Metabolic Primary Focus)
Sponsor Hub Sector Protocols Active Completed FDA NDA/BLA
Eli Lilly and Company Biopharma Industry 334 146 156 88
Novo Nordisk Biopharma Industry 176 60 104 20
Boehringer Ingelheim Biopharma Industry 139 45 70 54
Fujian Shengdi Pharmaceutical Co Biopharma Industry 37 21 13 0
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Federal / Public Agency 28 17 4 0
Hangzhou Zhongmei Huadong Pharmaceutical Co Biopharma Industry 24 16 6 0
Jaeb Center for Health Research Academic / Institutional Sponsor 21 11 6 0
University of Guadalajara Academic / Institutional Sponsor 19 4 7 0
Gan & Lee Pharmaceuticals Biopharma Industry 15 15 0 0
Medical University of Warsaw Academic / Institutional Sponsor 15 4 4 0
Rhythm Pharmaceuticals Biopharma Industry 15 5 10 0

3. Representative Multi-Center Phase II & III Endocrinology, Obesity, and Metabolic Studies

Indexed ClinicalTrials.gov v2 Study Dossiers in Endocrinology, Obesity, and Metabolic
NCT Study Protocol Brief Title Sponsor Phase Status
NCT07515079 Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema Bio-Thera Solutions Phase III RECRUITING
NCT07303803 A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus Shanghai Jiao Tong University School of Medicine Phase II RECRUITING
NCT07088068 A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes Sanofi Phase III RECRUITING
NCT06962098 Efficacy and Safety Study of Isuzinaxib in Subjects With DKD Aptabio Therapeutics Phase II RECRUITING
NCT04786262 A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes Vertex Pharmaceuticals Phase III RECRUITING
NCT07589608 A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight Eli Lilly and Company Phase II RECRUITING
NCT07335601 Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH Madrigal Pharmaceuticals Phase II RECRUITING
NCT06143956 A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight Eli Lilly and Company Phase II RECRUITING
NCT07845500 A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity Pfizer Phase III RECRUITING
NCT06672939 A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities Eli Lilly and Company Phase III RECRUITING
NCT06672549 A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Eli Lilly and Company Phase III RECRUITING
NCT07340320 A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus Corxel Pharmaceuticals Phase II RECRUITING
NCT03633708 A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis Amgen Phase III RECRUITING
NCT06739122 A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) Eli Lilly and Company Phase III RECRUITING
NCT07670416 A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes Roche / Genentech Phase III RECRUITING
NCT07296484 Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) Sparrow Pharmaceuticals Phase II RECRUITING

Related Therapeutic Condition Hubs & Crosswalks

Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI